DSGN vs. PHVS, AVBP, COGT, OCS, BCYC, DNA, IMNM, AVDL, CVAC, and CDMO
Should you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Pharvaris (PHVS), ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), Oculis (OCS), Bicycle Therapeutics (BCYC), Ginkgo Bioworks (DNA), Immunome (IMNM), Avadel Pharmaceuticals (AVDL), CureVac (CVAC), and Avid Bioservices (CDMO). These companies are all part of the "pharmaceutical products" industry.
Design Therapeutics vs.
Pharvaris (NASDAQ:PHVS) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, community ranking, analyst recommendations, dividends, media sentiment and earnings.
56.6% of Design Therapeutics shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by insiders. Comparatively, 31.2% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Pharvaris is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.
Pharvaris currently has a consensus target price of $40.50, suggesting a potential upside of 145.60%. Design Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 42.57%. Given Pharvaris' stronger consensus rating and higher probable upside, analysts clearly believe Pharvaris is more favorable than Design Therapeutics.
Pharvaris has a beta of -3.08, indicating that its stock price is 408% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500.
In the previous week, Pharvaris' average media sentiment score of 0.00 equaled Design Therapeutics'average media sentiment score.
Pharvaris received 26 more outperform votes than Design Therapeutics when rated by MarketBeat users. Likewise, 66.67% of users gave Pharvaris an outperform vote while only 33.33% of users gave Design Therapeutics an outperform vote.
Design Therapeutics' return on equity of -18.01% beat Pharvaris' return on equity.
Summary
Design Therapeutics beats Pharvaris on 8 of the 13 factors compared between the two stocks.
Get Design Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Design Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:DSGN) was last updated on 2/23/2025 by MarketBeat.com Staff
